What's Happening?
NeuroPace, a medical device company, reported a 24% increase in revenue for the fourth quarter of 2025, reaching $26.6 million. This growth was primarily driven by a 26% increase in sales of its RNS system, a neuromodulation device for treating epilepsy.
The company also reported a positive adjusted EBITDA of $900,000, marking its second consecutive quarter of profitability. NeuroPace's gross margin improved to 77.4%, supported by higher-margin RNS revenue and manufacturing efficiencies. The company is focusing on expanding the adoption of its RNS system and preparing for future indication expansions, including a potential new indication for idiopathic generalized epilepsy (IGE).
Why It's Important?
NeuroPace's strong financial performance underscores the growing demand for its RNS system, which offers a novel treatment option for patients with drug-resistant epilepsy. The company's focus on expanding indications for its device could significantly increase its market reach and impact. The potential approval of the RNS system for IGE, a condition with limited treatment options, represents a substantial growth opportunity. NeuroPace's strategic investments in AI-enabled tools and remote care capabilities aim to enhance clinical efficiency and patient outcomes, positioning the company for long-term success in the neuromodulation market.
What's Next?
NeuroPace is actively engaging with the FDA to secure approval for the expanded use of its RNS system in treating IGE. The company plans to launch its SeizureID tool, an AI-enabled software designed to improve clinical workflow, in 2026. NeuroPace is also investing in its nurse navigator team to enhance patient management and streamline the treatment process. As the company transitions to focus on its core RNS operations, it aims to achieve sustainable profitability and expand its market presence. The outcome of the FDA review and the successful implementation of new technologies will be critical to NeuroPace's future growth.
